Abstract
Mass spectrometry-based technologies are increasingly utilized in drug discovery. Phosphoproteomics in particular has allowed for the efficient surveying of phosphotyrosine signaling pathways involved in various diseases states, most prominently in cancer. We describe a phosphotyrosine-based proteomics screening approach to identify signaling pathways and tyrosine kinase inhibitor targets in highly tumorigenic human lymphoma-like primary cells. We identified several receptor tyrosine kinase pathways and validated SRC family kinases (SFKs) as potential drug targets for targeted selection of small molecule inhibitors. BMS-354825 (dasatinib) and SKI-606 (bosutinib), second and third generation clinical SFK/ABL inhibitors, were found to be potent cytotoxic agents against tumorigenic cells with low toxicity to normal pediatric stem cells. Both SFK inhibitors reduced ERK1/2 and AKT phosphorylation and induced apoptosis. This study supports the adaptation of high-end mass spectrometry techniques for the efficient identification of candidate tyrosine kinases as novel therapeutic targets in primary cancer cell lines.
Keywords: Bosutinib, BMS-354825, dasatinib, kinase inhibitors, phosphoproteomics, SKI-606, Src family kinases.
Current Drug Discovery Technologies
Title:A Phosphoproteomics Approach to Identify Candidate Kinase Inhibitor Pathway Targets in Lymphoma-Like Primary Cell Lines
Volume: 10 Issue: 4
Author(s): Miliana Vojvodic, Loen M. Hansford, Olena Morozova, Kim M. Blakely, Paul Taylor, Kelly E. Fathers, Jason Moffat, Marco Marra, Kristen M. Smith, Michael F. Moran and David R. Kaplan
Affiliation:
Keywords: Bosutinib, BMS-354825, dasatinib, kinase inhibitors, phosphoproteomics, SKI-606, Src family kinases.
Abstract: Mass spectrometry-based technologies are increasingly utilized in drug discovery. Phosphoproteomics in particular has allowed for the efficient surveying of phosphotyrosine signaling pathways involved in various diseases states, most prominently in cancer. We describe a phosphotyrosine-based proteomics screening approach to identify signaling pathways and tyrosine kinase inhibitor targets in highly tumorigenic human lymphoma-like primary cells. We identified several receptor tyrosine kinase pathways and validated SRC family kinases (SFKs) as potential drug targets for targeted selection of small molecule inhibitors. BMS-354825 (dasatinib) and SKI-606 (bosutinib), second and third generation clinical SFK/ABL inhibitors, were found to be potent cytotoxic agents against tumorigenic cells with low toxicity to normal pediatric stem cells. Both SFK inhibitors reduced ERK1/2 and AKT phosphorylation and induced apoptosis. This study supports the adaptation of high-end mass spectrometry techniques for the efficient identification of candidate tyrosine kinases as novel therapeutic targets in primary cancer cell lines.
Export Options
About this article
Cite this article as:
Vojvodic Miliana, Hansford M. Loen, Morozova Olena, Blakely M. Kim, Taylor Paul, Fathers E. Kelly, Moffat Jason, Marra Marco, Smith M. Kristen, Moran F. Michael and Kaplan R. David, A Phosphoproteomics Approach to Identify Candidate Kinase Inhibitor Pathway Targets in Lymphoma-Like Primary Cell Lines, Current Drug Discovery Technologies 2013; 10 (4) . https://dx.doi.org/10.2174/15701638113109990001
DOI https://dx.doi.org/10.2174/15701638113109990001 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microarray Technology as a Universal Tool for High-Throughput Analysis of Biological Systems
Combinatorial Chemistry & High Throughput Screening MicroRNA Regulatory Network in Human Colorectal Cancer
Mini-Reviews in Medicinal Chemistry Application of Nano- and Micro-Particles on the Topical Therapy of Skin-Related Immune Disorders
Current Pharmaceutical Design Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile
Current Drug Safety Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation
Current Pharmaceutical Design Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets Development of Medical Images in Differentiating Benign from Malignant Thyroid Nodules
Current Medical Imaging Identification of Novel Potent Inhibitors Against Bcl-xL Anti-apoptotic Protein Using Docking Studies
Protein & Peptide Letters Targeting mTOR Signaling Pathway in Ovarian Cancer
Current Medicinal Chemistry A Review on Antiproliferative and Apoptotic Activities of Natural Honey
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in the Third Generation Inhibitors of Bcr-Abl for Overriding T315I Mutation
Current Medicinal Chemistry Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Cancer Nanotechnology - Prospects for Cancer Diagnostics and Therapy
Current Cancer Therapy Reviews Transient Production of Recombinant Pharmaceutical Proteins in Plants: Evolution and Perspectives
Current Medicinal Chemistry Role of the Hypoxic Microenvironment in the Antitumor Activity of Tyrosine Kinase Inhibitors
Current Medicinal Chemistry The Roles of Sox Family Genes in Sarcoma
Current Drug Targets Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design Dysregulated NF-κB Pathway in Peripheral Mononuclear Cells of Alzheimers Disease Patients
Current Alzheimer Research The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets Clinical Application of Lentiviral Vectors – Concepts and Practice
Current Gene Therapy